Evidence map›Paper›PMID 28584963›Full record

ArticleInternational journal of hematology2017

Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF-β in the bone marrow: a case report.

Hiroshi Ohkawara, Miki Furukawa, Kazuhiko Ikeda, Akiko Shichishima-Nakamura, Masahiko Fukatsu, Takahiro Sano, Koki Ueda, Satoshi Kimura, Risa Kanai, Yuka Oka and 5 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Cytopenias in Autoimmune Liver Diseases-A Review.Journal of clinical medicine · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Hiroshi OhkawaraDepartment of Hematology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan. ohkawara@fmu.ac.jp.
Miki FurukawaDepartment of Hematology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Kazuhiko IkedaDepartment of Hematology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Akiko Shichishima-NakamuraDepartment of Hematology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Masahiko FukatsuDepartment of Hematology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Takahiro SanoDepartment of Hematology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Koki UedaDepartment of Hematology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Satoshi KimuraDepartment of Hematology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Risa KanaiDepartment of Diagnostic Pathology, Fukushima Medical University, Fukushima, Japan.
Yuka OkaDepartment of Diagnostic Pathology, Fukushima Medical University, Fukushima, Japan.
Fumi MurakamiDepartment of Diagnostic Pathology, Fukushima Medical University, Fukushima, Japan.
Osamu SuzukiDepartment of Diagnostic Pathology, Fukushima Medical University, Fukushima, Japan.
Yuko HashimotoDepartment of Diagnostic Pathology, Fukushima Medical University, Fukushima, Japan.
Kazuei OgawaDepartment of Hematology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Takayuki IkezoeDepartment of Hematology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We here report a 47-year-old female with autoimmune myelofibrosis (AIMF) associated with liver damage caused by autoimmune hepatitis and Evans syndrome. Bone marrow biopsy revealed hypocellular marrow with grade 2 reticulin fibrosis and increased levels of B lymphocytes (CD20

Indexed as

Anemia, Hemolytic, AutoimmuneHepatitis, AutoimmunePrimary MyelofibrosisThrombocytopeniaBone MarrowDrug ResistanceFemaleHumansMiddle AgedPrednisoloneRituximabTransforming Growth Factor betaPrednisoloneRituximabTransforming Growth Factor betaAutoimmune hepatitisAutoimmune myelofibrosisEvans syndromeRituximabTransforming growth factor-β

Identifiers

PMID28584963
OpenAlexW2624283686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.